Full article: Treatment continuation and satisfaction in women using combined oral contraception with nomegestrol acetate and oestradiol: a multicentre, prospective cohort study (BOLERO)
![Teva Announces Sale of Remaining Assets in Specialty Global Women's Health Portfolio for $1.38 Billion – Sawaya Partners., LLC Teva Announces Sale of Remaining Assets in Specialty Global Women's Health Portfolio for $1.38 Billion – Sawaya Partners., LLC](https://www.sawayapartners.com/wp-content/uploads/2017/11/Teva-1170x560.jpg)
Teva Announces Sale of Remaining Assets in Specialty Global Women's Health Portfolio for $1.38 Billion – Sawaya Partners., LLC
![Safety results from large real-world safety study in combined oral contraception published | Business Wire Safety results from large real-world safety study in combined oral contraception published | Business Wire](https://mms.businesswire.com/media/20211014005804/en/916088/23/Theramex_logo_with_words_colour.jpg)
Safety results from large real-world safety study in combined oral contraception published | Business Wire
![Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal](https://media.bizj.us/view/img/10777492/47002105ovaleap300ie-0-5ml*750xx640-360-0-60.jpg)
Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal
![Safety results from large real-world safety study in combined oral contraception published | Business Wire Safety results from large real-world safety study in combined oral contraception published | Business Wire](https://mms.businesswire.com/media/20211014005804/en/916088/22/Theramex_logo_with_words_colour.jpg)